Objective To explore the application value of low dose Apatinib combined with superselectivetranscatheterarterial chemoembolization(S-TACE)in the treatment of PLC in advanced stage.Methods 102 patients with advanced primary liver cancer(PLC)in our hospital from January 2021 to January 2022 were randomly divided into two groups with 51 cases in each group.The control group was treated with S-TACE,and the study group was treated with low-dose Apatinib combined with S-TACE.The therapeutic effect,serum tumor markers[alpha feto protein(AFP),carbohydrate antigen 199(CA199),e-cadherin(EC)],immune function indicators[T lymphocytes(CD3+,CD4+),CD4+/CD8+],homologous proteins(SIX1,SIX2),adverse reactions and prognosis were compared between the two groups.Results The total effective rates of the study group at 3 and 6 months after surgery were 86.27％and 82.35％,respectively,which were higher than those of the control group(64.71％,58.82％)(P<0.05);the serum AFP,CA199,EC,SIX1,and SIX2 levels in the study group were(95.24±23.67)ng/mL,(47.31±8.52)U/L,(1 811.24±153.76)ng/mL,(52.71±7.38)ng/mL,and(49.83±6.59)ng/mL at 3 months after surgery,and the levels of these indicators were(101.65±24.83)ng/mL,(50.26±9.41)U/L,(1 856.32±160.25)ng/mL,(53.26±7.45)ng/mL,and(50.26±6.71)ng/mL at 6 months after surgery,which were lower than these in the control group[(119.86±25.40)ng/mL,(57.46±9.18)U/L,(1 923.57±166.02)ng/mL,(60.23±7.69)ng/mL,(57.61±7.02)ng/mL],(126.17±26.59)ng/mL,(60.08±9.77)U/L,(1 972.43±171 09)ng/mL,(62.11±7.90)ng/mL(58.19±7.35 ng/mL)](P<0.05);the levels of CD3+,CD4+,and CD4+/CD8+in the study group were(68.13±7.84)％,(36.48±2.75)％,and(1.31±0.23)at 3 months after surgery,and(66.75±8.04)％,(35.67±2.88)％,and(1.30±0.22)at 6 months after surgery,which were higher than those in the control group[(62.35±8.13)％,(33.75±2.91)％,(1.20±0.25)],[60.21±8.26)％,(32.86±3.10)％,and(1.18±0.26)](P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05);the one-year postoperative survival rate in the study group was 90.20％,which was higher than 74.51％in the control group(P<0.05).Conclusion Low dose Apatinib combined with S-TACE in the treatment of PLC can enhance the clinical efficacy,regulate the immune function,alleviate the disease of patients,and help to improve the survival prognosis,with high safety.
Primary liver cancerSuperselective trans catheter arterial chemoembolizationApatinibImmune function indexTumor markersHomologous proteinPrognosis
维普
万方数据
